South America Immunotherapy Drugs Market

ID: MRFR/Pharma/51858-HCR 200 Pages Vikita Thakur Last Updated: September 17, 2026
South America Immunotherapy Drugs Market Research Report: Size, Share, Trend Analysis By Therapeutic Area (Oncology, Autoimmune Disorders, Infectious Diseases, Allergy), By Drug Type (Monoclonal Antibodies, Checkpoint Inhibitors, Vaccines, Cytokines), By Route of Administration (Intravenous, Subcutaneous, Oral), By End Users (Hospitals, Research Institutions, Pharmaceutical Companies) and By Regional (Brazil, Mexico, Argentina, Rest of South America) - Growth Outlook & Industry Forecast 2025 To 2035
South America Immunotherapy Drugs Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)5.31%
2024 Market Size$ 3,583 Million
2025 Market Size$ 3,773.26 Million
2035 Market Size$ 6,330 Million
Key Players
Bristol-Myers Squibb
Merck & Co
Roche
Novartis
Amgen
Gilead Sciences
Trends
  • Increasing Investment in Research and Development
  • Regulatory Support for Innovative Therapies
  • Collaboration Between Local and International Firms
Opportunities
  • Rising Cancer Incidence
  • Collaborative Research Efforts
  • Government Initiatives and Funding
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Industrial Automation & Equipment, BY Therapeutic Area (USD Million)
      1. 4.1.1 Oncology
      2. 4.1.2 Autoimmune Disorders
      3. 4.1.3 Infectious Diseases
      4. 4.1.4 Allergy
    2. 4.2 Industrial Automation & Equipment, BY Drug Type (USD Million)
      1. 4.2.1 Monoclonal Antibodies
      2. 4.2.2 Checkpoint Inhibitors
      3. 4.2.3 Vaccines
      4. 4.2.4 Cytokines
    3. 4.3 Industrial Automation & Equipment, BY Route of Administration (USD Million)
      1. 4.3.1 Intravenous
      2. 4.3.2 Subcutaneous
      3. 4.3.3 Oral
    4. 4.4 Industrial Automation & Equipment, BY End User (USD Million)
      1. 4.4.1 Hospitals
      2. 4.4.2 Research Institutions
      3. 4.4.3 Pharmaceutical Companies
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Industrial Automation & Equipment
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Industrial Automation & Equipment
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Bristol-Myers Squibb (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Merck & Co (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Roche (CH)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Novartis (CH)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Amgen (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Gilead Sciences (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 AstraZeneca (GB)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Pfizer (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Eli Lilly and Company (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 SOUTH AMERICA MARKET ANALYSIS BY THERAPEUTIC AREA
    3. 6.3 SOUTH AMERICA MARKET ANALYSIS BY DRUG TYPE
    4. 6.4 SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    5. 6.5 SOUTH AMERICA MARKET ANALYSIS BY END USER
    6. 6.6 KEY BUYING CRITERIA OF INDUSTRIAL AUTOMATION & EQUIPMENT
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF INDUSTRIAL AUTOMATION & EQUIPMENT
    9. 6.9 DRIVERS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
    11. 6.11 SUPPLY / VALUE CHAIN: INDUSTRIAL AUTOMATION & EQUIPMENT
    12. 6.12 INDUSTRIAL AUTOMATION & EQUIPMENT, BY THERAPEUTIC AREA, 2024 (% SHARE)
    13. 6.13 INDUSTRIAL AUTOMATION & EQUIPMENT, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Million)
    14. 6.14 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DRUG TYPE, 2024 (% SHARE)
    15. 6.15 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DRUG TYPE, 2024 TO 2035 (USD Million)
    16. 6.16 INDUSTRIAL AUTOMATION & EQUIPMENT, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
    17. 6.17 INDUSTRIAL AUTOMATION & EQUIPMENT, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
    18. 6.18 INDUSTRIAL AUTOMATION & EQUIPMENT, BY END USER, 2024 (% SHARE)
    19. 6.19 INDUSTRIAL AUTOMATION & EQUIPMENT, BY END USER, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
      2. 7.2.2 BY DRUG TYPE, 2025-2035 (USD Million)
      3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
      4. 7.2.4 BY END USER, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

South America South America Immunotherapy Drugs Market Segmentation

South America Immunotherapy Drugs Market By Therapeutic Area (USD Million, 2025-2035)

  • Oncology
  • Autoimmune Disorders
  • Infectious Diseases
  • Allergy

South America Immunotherapy Drugs Market By Drug Type (USD Million, 2025-2035)

  • Monoclonal Antibodies
  • Checkpoint Inhibitors
  • Vaccines
  • Cytokines

South America Immunotherapy Drugs Market By Route of Administration (USD Million, 2025-2035)

  • Intravenous
  • Subcutaneous
  • Oral

South America Immunotherapy Drugs Market By End User (USD Million, 2025-2035)

  • Hospitals
  • Research Institutions
  • South America Immunotherapy Drugs Market Companies

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.